Supreme Court Ruling Bolsters Generic Drugmakers Over Branded Pharma in "Skinny Label" Dispute

The U.S. Supreme Court has declined to hear an appeal from Amarin Pharma, effectively upholding a lower court’s decision that favors generic drug manufacturers. This development reinforces the ability of generics to market less expensive versions of drugs with scaled-back labeling, impacting intellectual property norms in the pharmaceutical sector.

The nation's highest judicial body has opted not to review a pivotal case involving Amarin Pharma, thereby solidifying a previous appellate court judgment concerning so-called "skinny labels" for generic medications. This decision is seen as a significant win for companies producing generic drugs, providing them with greater flexibility in how they market their products. According to Seeking Alpha, the Supreme Court's refusal to grant a writ of certiorari means that the ruling by the U.S. Court of Appeals for the Federal Circuit remains in place. This appellate decision had reversed an earlier award of $2.35 billion in damages to Amarin Pharma, which was initially granted after a jury found that Hikma Pharmaceuticals had infringed on Amarin's patents. The core of the dispute revolves around the practice of "carve-out" labeling, often referred to as "skinny labeling." This allows generic manufacturers to omit patented indications from their product labels, thereby avoiding direct patent infringement while still bringing a more affordable version of a drug to market for unpatented uses. Amarin had contended that Hikma's generic equivalent of its fish-oil derived drug, Vascepa, still induced infringement even with a skinny label. Vascepa is prescribed for reducing cardiovascular risk in certain patients. Amarin had argued that despite the absence of specific patented indications on the generic version's label, physicians could still prescribe it for those uses, thus infringing on their intellectual property. The Federal Circuit, however, disagreed, emphasizing the importance of promoting generic drug competition and access to more affordable medicines. This outcome is anticipated to have broad implications across the pharmaceutical industry. It strengthens the position of generic drugmakers, potentially leading to more rapid market entry for generics and increased competition for branded pharmaceutical companies. For innovator companies like Amarin, it underscores the challenges of protecting intellectual property in a landscape that increasingly favors generic alternatives. Legal experts suggest that the Supreme Court's non-intervention signals a continued judicial inclination to support mechanisms that facilitate the availability of lower-cost generic drugs. This could encourage further use of skinny labels by generic manufacturers, potentially accelerating the erosion of market exclusivity for branded pharmaceuticals once their primary patents expire. The decision concludes a long-running legal battle and establishes a precedent that will likely influence future patent infringement cases in the pharmaceutical sector.